These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1845 related articles for article (PubMed ID: 27435396)

  • 61. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.
    Uchibori K; Inase N; Araki M; Kamada M; Sato S; Okuno Y; Fujita N; Katayama R
    Nat Commun; 2017 Mar; 8():14768. PubMed ID: 28287083
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells.
    Yonesaka K; Kobayashi Y; Hayashi H; Chiba Y; Mitsudomi T; Nakagawa K
    Oncol Rep; 2019 Feb; 41(2):1059-1066. PubMed ID: 30483795
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo.
    Liu Z; Gao W
    Arch Toxicol; 2019 Jun; 93(6):1555-1571. PubMed ID: 30993382
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
    Li XF; Shen WZ; Jin X; Ren P; Zhang J
    Sci Rep; 2020 Jul; 10(1):11236. PubMed ID: 32641854
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Osimertinib for the treatment of patients with
    Alsharedi M; Bukamur H; Elhamdani A
    Drugs Today (Barc); 2018 Jun; 54(6):369-379. PubMed ID: 29998228
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD).
    Yu HA; Goldberg SB; Le X; Piotrowska Z; Goldman JW; De Langen AJ; Okamoto I; Cho BC; Smith P; Mensi I; Ambrose H; Kraljevic S; Maidment J; Chmielecki J; Li-Sucholeiki X; Doughton G; Patel G; Jewsbury P; Szekeres P; Riess JW
    Clin Lung Cancer; 2021 Nov; 22(6):601-606. PubMed ID: 34389237
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway.
    Wang H; Du X; Liu W; Zhang C; Li Y; Hou J; Yu Y; Li G; Wang Q
    Respir Res; 2024 May; 25(1):215. PubMed ID: 38764025
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Real-World Pattern of Treatment and Clinical Outcomes of EGFR-Mutant Non-Small Cell Lung Cancer in a Single Academic Centre in Quebec.
    Agulnik JS; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Small D
    Curr Oncol; 2021 Dec; 28(6):5179-5191. PubMed ID: 34940073
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Inhibition of Bcl-2 and Bcl-xL overcomes the resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer.
    Lu Y; Bian D; Zhang X; Zhang H; Zhu Z
    Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33200796
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
    Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ
    BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564
    [TBL] [Abstract][Full Text] [Related]  

  • 71. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
    Yiming R; Takeuchi Y; Nishimura T; Li M; Wang Y; Meguro-Horike M; Kohno T; Horike SI; Nakata A; Gotoh N
    Cancer Sci; 2021 Sep; 112(9):3810-3821. PubMed ID: 34145929
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.
    Ramalingam SS; Yang JC; Lee CK; Kurata T; Kim DW; John T; Nogami N; Ohe Y; Mann H; Rukazenkov Y; Ghiorghiu S; Stetson D; Markovets A; Barrett JC; Thress KS; Jänne PA
    J Clin Oncol; 2018 Mar; 36(9):841-849. PubMed ID: 28841389
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
    Girard N
    Future Oncol; 2018 May; 14(11):1117-1132. PubMed ID: 29336166
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
    Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.
    Jiang XM; Xu YL; Huang MY; Zhang LL; Su MX; Chen X; Lu JJ
    Acta Pharmacol Sin; 2017 Nov; 38(11):1512-1520. PubMed ID: 28880013
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer.
    Takahashi A; Seike M; Chiba M; Takahashi S; Nakamichi S; Matsumoto M; Takeuchi S; Minegishi Y; Noro R; Kunugi S; Kubota K; Gemma A
    Sci Rep; 2018 Oct; 8(1):14896. PubMed ID: 30291293
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.
    Uchibori K; Inase N; Nishio M; Fujita N; Katayama R
    J Thorac Oncol; 2018 Jul; 13(7):915-925. PubMed ID: 29702287
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
    Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
    Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
    Lu S; Shih JY; Jang TW; Liam CK; Yu Y
    Adv Ther; 2021 May; 38(5):2038-2053. PubMed ID: 33730350
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset.
    Cho BC; Chewaskulyong B; Lee KH; Dechaphunkul A; Sriuranpong V; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cheng Y; Cho EK; Voon PJ; Lee JS; Mann H; Saggese M; Reungwetwattana T; Ramalingam SS; Ohe Y
    J Thorac Oncol; 2019 Jan; 14(1):99-106. PubMed ID: 30240852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 93.